In our meta-analysis, a study by Dinis-Ribeiro et al. [21] included high-risk patients of GC, such as those with AG, IM, or dysplasia, excluding the healthy population, and showed higher sensitivity compared to that of pooled analysis with cut-off of PG I/PG II ratio ≤3 (0.66 vs. 0.50) (Table 5). This evidence concerns the gene JUP and gastric cancer.